Evidence mapPaperPMID 31288625Full record

ReviewOpen biology2019

The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde?

Diana Vara-Ciruelos, Fiona M Russell, D Grahame Hardie

Open access · goldAbstract readReview
In one paragraph

Review in Open biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Translational control of AMPK activity in melanoma.Cell communication and signaling : CCS · 2026
    Article
  5. Article
  6. Mitochondrial Dysfunction inTransboundary and emerging diseases · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Diana Vara-CiruelosDivision of Cell Signalling and Immunology, School of Life Sciences, University of Dundee , Dow Street, Dundee DD1 5EH , UK.
Fiona M RussellDivision of Cell Signalling and Immunology, School of Life Sciences, University of Dundee , Dow Street, Dundee DD1 5EH , UK.
D Grahame HardieDivision of Cell Signalling and Immunology, School of Life Sciences, University of Dundee , Dow Street, Dundee DD1 5EH , UK.
University of Dundee · GB

Funding

Cancer Research UK 15101Cancer Research UK C37030/A15101Wellcome Trust 204766/Z/16/Z
6 · The paper itself

Abstract

The AMP-activated protein kinase (AMPK) acts as a cellular energy sensor. Once switched on by increases in cellular AMP : ATP ratios, it acts to restore energy homeostasis by switching on catabolic pathways while switching off cell growth and proliferation. The canonical AMP-dependent mechanism of activation requires the upstream kinase LKB1, which was identified genetically to be a tumour suppressor. AMPK can also be switched on by increases in intracellular Ca

Indexed as

AMP-Activated Protein KinasesAnimalsEnergy MetabolismGenes, Tumor SuppressorGlucoseHumansMiceNeoplasmsProtein Kinase InhibitorsSignal TransductionAMP-Activated Protein KinasesGlucoseProtein Kinase InhibitorsAMPKcancerLKB1metabolismtumour promoterstumour suppressors

Identifiers

PMID31288625
PMCPMC6685927
OpenAlexW2956551720

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.